Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 9/20 | 1.00 |
| ▸ | TACR1 | P25103 | 9/20 | 1.00 |
| ▸ | TACR3 | P29371 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4208412 | 1.00 | TACR2 (1.00) | TACR2TACR1TACR3HRH1 | |
| SCHEMBL4208415 | 1.00 | TACR2 (1.00) | TACR2TACR1TACR3HRH1 | |
| Hydrochloric Acid SCHEMBL29404822 | 0.99 | TACR2 (0.98) | TACR2TACR1TACR3HRH1 | |
| Hydrochloric Acid SCHEMBL15798575 | 0.99 | TACR2 (0.98) | TACR2TACR1TACR3HRH1 | |
| Hydrochloric Acid SCHEMBL7465619 | 0.99 | TACR2 (0.98) | TACR2TACR1TACR3HRH1 | |
| Hydrochloric Acid SCHEMBL4354212 | 0.98 | TACR2 (0.97) | TACR2TACR1TACR3HRH1 | |
| Maleic Acid SCHEMBL8906027 | 0.96 | TACR2 (0.93) | TACR2TACR1TACR3HRH1 | |
| Fumaric Acid SCHEMBL8906036 | 0.96 | TACR2 (0.93) | TACR2TACR1TACR3HRH1 | |
| SCHEMBL8641310 | 0.96 | TACR2 (0.91) | TACR2TACR1TACR3HRH1 | |
| SCHEMBL8635846 | 0.95 | TACR2 (0.91) | TACR2TACR1TACR3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404679-B2 | Pyrrolidine derivatives as NK2 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120208803-A1 | PYRROLIDINE DERIVATIVES AS NK2 RECEPTOR ANTAGONISTS | BISSANTZ CATERINA (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20090312327-A1 | PYRROLIDINE DERIVATIVES AS NK2 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090264388-A1 | Compounds and Methods of Treating Disorders Associated With Activation of Metachromatic Cells | VALORISATION RECHERCHE HSCM, LIMITED PARTNERSHIP (CA) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264388-A1 | Compounds and Methods of Treating Disorders Associated With Activation of Metachromatic Cells | CMA1, HRH4, MRGPRX4 | TACR2 86/4885TACR1 111/4885TACR3 137/4885 |
| US-20090312327-A1 | PYRROLIDINE DERIVATIVES AS NK2 RECEPTOR ANTAGONISTS | TACR2, PRLHR, AVPR2 | TACR2 1/4885TACR1 15/4885TACR3 147/4885 |
| US-20120208803-A1 | PYRROLIDINE DERIVATIVES AS NK2 RECEPTOR ANTAGONISTS | TACR2, PRLHR, AVPR2 | TACR2 1/4885TACR1 15/4885TACR3 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.